IL-17A and IL-17F, are pro-inflammatory cytokines that drive skin and joint inflammation. Sonelokimab's dual neutralization more comprehensively inhibits the IL-17 pathway compared to selective IL-17A inhibitors, potentially offering enhanced efficacy in reducing psoriatic lesions, joint damage, and systemic inflammation. Its small size may also improve tissue penetration.